Bone-pathobolism treating agent
US6919312B2 · kind B2 · utility
2Cited by
11References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2001 |
| Grant date | Jul 19, 2005 |
| Priority date | — |
| Expiry date | Sep 22, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/36
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel bone-pathobolism treating agent is provided. A bone-pathobolism treating agent comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants, and a polysaccharide or its derivatives. As the polysaccharide or its derivatives, heparin, dextran sulfate and the like can be used. A bone-pathobolism treating agent is provided which has excellent therapeutic effect on bone-pathobolism such as osteoporosis, hypercalcemia, or chronic articular rheumatism and persistance of the activity. The agent is useful as a medicine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.